Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by GlaxoSmithKline
Sponsor:
Collaborators:
Imperial College London
Heart Hospital
Royal Free Hospital NHS Foundation Trust
Quintiles London
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01777243
First received: January 24, 2013
Last updated: October 30, 2014
Last verified: October 2014

January 24, 2013
October 30, 2014
May 2013
November 2015   (final data collection date for primary outcome measure)
  • Safety of GSK2398852 as assessed by number of subjects with AEs in Part A and in Part B [ Time Frame: Continuous throughout the study ] [ Designated as safety issue: No ]
    Adverse events (AEs) will be collected from the start of Study Treatment and until the follow-up contact.
  • Safety of GSK2398852 as assessed by clinical laboratory tests in Part A and in Part B [ Time Frame: At scheduled intervals upto Day 42 in each Part. ] [ Designated as safety issue: No ]
    Safety data will include assessments of clinical laboratory tests (hematology, clinical chemistry and urinalysis).
  • Safety of GSK2398852 as assessed by vital signs measurements in Part A and in Part B [ Time Frame: At scheduled intervals upto Day 42 in each Part. ] [ Designated as safety issue: No ]
    Safety data will include measurements of vital signs (semi supine systolic and diastolic blood pressure, pulse rate and temperature measured orally).
  • Safety of GSK2398852 as assessed by ECG readings in Part A and in Part B [ Time Frame: At scheduled intervals upto Day 42 in each Part. ] [ Designated as safety issue: No ]
    Safety data will include single 12-lead electrocardiogram (ECG) readings obtained at each timepoint during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.
  • PK profile of GSK2315698 and GSK2398852 in Part A and in Part B [ Time Frame: In Part A and Part B on Day -2, Day 1 (pre-dose, 1 hour [hr], 2 hr, 3 hr, 4 hr, 8 hr, 12 hr), Day 2, Day 3, Day 4, Day 6, Day 14, Day 21, Day 42 ] [ Designated as safety issue: No ]
    Pharmacokinetic (PK) profile GSK2315698 and GSK2398852 was performed to evaluate PK of single doses of GSK2398852 and GSK2315698 when co-administered.
  • Dose response of single doses of GSK2398852 when co-administered with GSK2315698 in Part B [ Time Frame: Baseline, Day 6, Day 14 and Day 42 in Part B. ] [ Designated as safety issue: No ]
    The main measure of dose response will be determined by information from part A (and Part A extension if required). The options are: -Volume of distribution of gadolinium in the spleen as a measure of amyloid load (EqMRI); and -Liver histology examination for presence of giant cells, activation of macrophages, and amyloid clearance.
Same as current
Complete list of historical versions of study NCT01777243 on ClinicalTrials.gov Archive Site
  • SAP concentrations measurement [ Time Frame: Baseline, Day -3, Day -2, Day -1, Day 42 in each Part. ] [ Designated as safety issue: No ]
    SAP concentrations before administration of GSK2398852 will be measured using Hycult ELISA assay; and SAP concentrations after administration of GSK2398852 will be measured by GSK assay in both Parts.
  • Measurement of anti-drug antibodies before and after treatment with GSK2398852 [ Time Frame: Day 1 pre-dose, Day 21, Day 42 in each Part. ] [ Designated as safety issue: No ]
    Anti-drug antibodies before and after treatment with GSK2398852 will be measured to assess the immunogenicity of GSK2398852 when co-administered with GSK2315698.
Same as current
Not Provided
Not Provided
 
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
A Single Dose First in Human Study of GSK2398852 Co-Administered With GSK2315698 in Patients With Systemic Amyloidosis

The study will be conducted in two parts. The first (Part A) will be an open label single dose escalation part beginning with the proposed starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable doses until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 nanogram/millilitre (ng/mL). Decisions about these next dose levels will be made following safety review of the prior subjects' data; dose levels may be changed (increased and lowered) and dose levels may be repeated depending on the observed safety such that Part A extension study may be performed. In addition, pharmacokinetics of GSK2315698 (SAP depleter) and GSK2398852 (anti-SAP mAb), and circulating SAP concentrations will be assessed. Dose escalation in Part A will continue to the highest well tolerated dose or the highest allowable dose. Subjects will be closely monitored and will undergo Equilibrium contrast Magnetic Resonance Imaging (EqMRI) including organ volume, Elastography and Liver Biopsy if required.

Part B will be a randomized partially blinded part with the principal objective of assessing the dose response of the GSK2398852 in more detail. Subjects will be assigned to one of approximately 5 dose groups from Part A. The precise selection of numbers of subjects and dose levels will be informed by the results from Part A.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Amyloidosis
  • Drug: GSK2398852
    Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg [approximately equivalent to 0.1 mg/ kg]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
  • Drug: GSK2315698
    Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
  • Experimental: Part A Arm
    Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
    Interventions:
    • Drug: GSK2398852
    • Drug: GSK2315698
  • Experimental: Part B Arm
    The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
    Interventions:
    • Drug: GSK2398852
    • Drug: GSK2315698
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
46
November 2015
November 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject has been medically diagnosed with systemic amyloidosis and falls into one of the patient groups (small to moderate amyloid load involving the spleen for Part A; moderate to large amyloid load involving the spleen (to a moderate/large extent) for Part A (following agreement from external safety committee); moderate to large amyloid load involving the spleen and liver (spleen involved to a moderate/large extent) for Part A extension (if required); and moderate to large amyloid load involving the spleen (and liver in subset of subjects only) for Part B).
  • Alanine aminotransferase (ALT) <3x upper limit of normal (ULN) and bilirubin <1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.
  • Subject is ambulant and capable of attending for the study visit schedule.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • A female subject is eligible to participate if she is of non-childbearing potential; or females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the approved contraception methods.
  • Male subjects with female partners of child-bearing potential must agree to use one of the approved contraception methods.
  • Smokers (<10 /day) are permitted but must be willing to abstain for the duration of residential study sessions

Exclusion Criteria:

  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  • The subject has participated in a clinical trial and has received an investigational therapeutic product (unlicensed) within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). This timeframe will not apply to short term administration of GSK2315698 in study CPH114527.
  • Pregnant females as determined by positive serum or urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.
  • Lactating females.
  • Estimated glomerular filtration rate (GFR)<30 milliliter (mL)/minute (min) [<60 mL/min for the first 4 subjects to be enrolled]
  • Evidence of an active urinary sediment on microscopy as evidenced by the presence of red cell casts
  • Decompensated cardiac failure or a recent history of syncope associated with cardiac disease.
  • In a subject in whom there is a clinical suspicion of cardiac amyloid, an echocardiogram is consistent with significant cardiac amyloid, whether symptomatic or not.
  • Clinically significant anaemia- hemoglobin (Hb) <9 gram (g)/deciliter (dL).
  • Use of prohibited medications.
  • Poor or unsuitable venous access.
  • Subjects with a QT interval corrected using Fridericia's formulas (QTcF) of >480 ms or other electrocardiogram (ECG) abnormalities which, in the opinion of the investigator are clinically significant and may increase safety risk.
  • Uncontrolled hypertension with systolic blood pressure (BP) >170 mmHg and /or diastolic >100 mmHg
  • Presence of any co-morbid condition (e.g. severe or unstable coronary artery disease; moderate-severe chronic obstructive pulmonary disease) which in the opinion of the investigator would increase the potential risk to the subject.
  • Subjects with active vasculitis
  • Exclusions from Equilibrium contrast Magnetic Resonance Imaging (EqMRI) scanning [Contraindications to Magnetic Resonance Imaging (MRI) scanning including, but not limited to: Intracranial aneurism clips (except Sugita); History of intra-orbital metal fragments that have not been removed by an MD (as confirmed by orbital X-Ray); Pacemakers and non-MR compatible heart valves; Inner ear implants; History of claustrophobia; estimated GFR <30 mL/min (gadolinium exclusion)]
  • Subjects with dementia or a diagnosis of cerebral amyloid angiopathy.
Both
18 Years to 70 Years
No
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
United Kingdom
 
NCT01777243
115570
Yes
GlaxoSmithKline
GlaxoSmithKline
  • Imperial College London
  • Heart Hospital
  • Royal Free Hospital NHS Foundation Trust
  • Quintiles London
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP